Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959817 | 0.92 | KDM1A (0.41) | DRD4SLC6A4KDM1AMAOAMAOB | |
| SCHEMBL4959798 | 0.92 | KDM1A (0.41) | DRD4SLC6A4KDM1AMAOAMAOB | |
| SCHEMBL4960077 | 0.83 | ALDH1A1 (0.48) | SLC6A4KDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL4958526 | 0.82 | ALDH1A1 (0.42) | DRD4SLC6A4ALDH1A1GLAPTGER1 | |
| SCHEMBL4958534 | 0.82 | ALDH1A1 (0.42) | DRD4SLC6A4ALDH1A1GLAPTGER1 | |
| SCHEMBL1041768 | 0.79 | KDM1A (0.49) | SLC6A4KDM1AMAOAMAOBALDH1A1 | |
| SCHEMBL4175275 | 0.78 | SLC6A4 (0.57) | DRD4SLC6A4HTR2CHTR2BALDH1A1 | |
| SCHEMBL3354689 | 0.78 | SLC6A4 (0.57) | DRD4SLC6A4HTR2CHTR2BALDH1A1 | |
| SCHEMBL4958842 | 0.77 | MAOB (0.42) | KDM1ACNR1MRGPRX4MAOBPTGER1 | |
| SCHEMBL4960084 | 0.77 | ALDH1A1 (0.48) | DRD4ALDH1A1GLAPTGER1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | DRD4 71/4885SLC6A4 213/4885KDM1A 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.